March 3, 2026Open Access

Direct targeting of STAT3 by xanthatin suppresses allergic airway inflammation via inhibition of TSLP release and NK2 cell polarization

Key Points

STAT3 inhibition leads to decreased allergic airway inflammation and is tied to xanthatin's effects.
With xanthatin treatment, TSLP levels drop significantly, indicating a successful therapeutic mechanism.
Analysis includes targeting the TSLP/STAT3 axis in epithelial cells to improve market prospects for asthma.
This targeted therapy may enable new pathways for asthma management, calling for further testing of xanthatin.

Abstract

Xanthatin ameliorates allergic airway inflammation by directly targeting STAT3, thereby dually inhibiting the TSLP/STAT3 axis in epithelial cells and the subsequent STAT3-dependent differentiation of pathogenic NK2 cells, presenting a promising multi-targeted strategy for asthma treatment.

Direct targeting of STAT3 by xanthatin suppresses allergic airway inflammation via inhibition of TSLP release and NK2 cell polarization

Key Points

Abstract

Cite This Study